Nordion Inc. launches review of strategic alternatives, hires Jefferies & Co.

OTTAWA – Shares of medical isotope company Nordion Inc. (TSX:NDN) jumped more than 10 per cent after it launched a review of strategic alternatives.

The company says it has hired investment firm Jefferies and Co. to help conduct the review.

Nordion cautioned that there could be no assurance anything would come of the process, but strategic reviews are often prelude the sale of a company.

The review came as Nordion reported a fourth-quarter loss of US$43.5 million or 70 cents per share compared with a profit of US$6.9 million or 11 cents per share a year ago.

Revenue for the quarter ended Oct. 31 totalled $74.7 million, up from $74 million.

Excluding one-time items including $24.1 million in litigation accruals and $35.4 million related to deferred tax assets, the company said it earned $21.4 million or 34 cents per share, up from $18.7 million or 30 cents per share a year ago.

Shares in the company were up 91 cents at $7.34 in trading on the Toronto Stock Exchange.

News from © The Canadian Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Canadian Press

The Canadian Press is Canada's trusted news source and leader in providing real-time, bilingual multimedia stories across print, broadcast and digital platforms.